American Well (AMWL) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
4 Nov, 2026Executive summary
Q3 revenue was $49.0M, above guidance; adjusted EBITDA loss was $3.6M, and operating loss narrowed to $11.7M from $29.3M. Positive operating cash flow and adjusted EBITDA are targeted for Q4.
FY 2026 revenue and adjusted EBITDA outlooks were raised; AMG visit guidance remained 1.32M–1.37M.
Strategy centers on one branded platform to activate members, integrate care programs and measure outcomes; more than 90 million covered lives are served.
Financial highlights
Q3 revenue was $49.0M, down 12.9% YoY and $1M above the high end of guidance; gross profit was $26M.
Q3 operating expenses, including D&A, were $37.6M, down 36.1% YoY; total operating costs and expenses declined 29% to $60.6M.
Adjusted EBITDA loss was $3.6M vs. $12.7M in Q3 2025; operating loss was $11.7M vs. $29.3M.
9M revenue was $155.9M vs. $194.0M; adjusted EBITDA loss was $7.8M vs. $29.6M.
9M net loss was $30.9M vs. $69.8M; cash used in operating activities was $1.9M vs. $48.6M.
Outlook and guidance
FY 2026 revenue guidance increased to $204M–$206M; adjusted EBITDA loss guidance improved to $6.9M–$7.9M.
Q4 revenue guidance is $48M–$50M; adjusted EBITDA guidance is break-even to +$1M, with positive operating cash flow targeted.
FY AMG visits are expected at the high end of 1.32M–1.37M.
2027 growth depends partly on government contract timing; opportunities may start during 2027 rather than January 1, with guidance planned for the next earnings call.
Existing cash and cash equivalents are expected to cover working capital and capital expenditure needs for at least 12 months, though some future operating losses are expected.
Latest events from American Well
- Focused on government and payer markets, driving growth with SaaS and disciplined execution.AMWL
Morgan Stanley 24th Annual Global Healthcare Conference - Q2 2026 revenue hit $52M, net loss narrowed, and 2026 outlook was raised with positive cash flow projected.AMWL
Q2 2026 - Digital care platform advances risk-based models, grows subscription revenue, and nears DHA global rollout.AMWL
UBS Global Healthcare Conference - Director election, auditor ratification, and executive pay were key AGM agenda items.AMWL
AGM 2026 - Dr. Roy Schoenberg will not seek re-election, and no substitute director will be nominated.AMWL
Proxy filing - Strong Q1 results and major government contracts position the company for profitable growth by 2027.AMWL
21st Annual Needham Technology, Media, & Consumer Conference - Q1 2026 revenue fell 18%, but net loss narrowed and positive cash flow is targeted for Q4.AMWL
Q1 2026 - Key votes include director elections, auditor ratification, and executive pay approval.AMWL
Proxy filing - Margins improved and losses narrowed, with positive cash flow targeted for Q4 2026.AMWL
Q4 2025